ALRNAILERON THERAPEUTICS INC

Nasdaq aileronrx.com


$ 5.01 $ 0.46 (10.11 %)    

Thursday, 18-Apr-2024 15:57:18 EDT
QQQ $ 423.30 $ -3.61 (-0.85 %)
DIA $ 377.76 $ -1.13 (-0.3 %)
SPY $ 499.97 $ -1.73 (-0.34 %)
TLT $ 88.82 $ -0.43 (-0.48 %)
GLD $ 220.32 $ -0.55 (-0.25 %)
$ 4.25
$ 4.55
$ 0.00 x 0
$ 12.00 x 100
$ 4.55 - $ 7.36
$ 1.01 - $ 7.12
65,951
na
19.54M
$ 1.52
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 04-15-2024 12-31-2023 10-K
2 10-13-2023 09-30-2023 10-Q
3 08-11-2023 06-30-2023 10-Q
4 05-08-2023 03-31-2023 10-Q
5 03-20-2023 12-31-2022 10-K
6 11-01-2022 09-30-2022 10-Q
7 08-15-2022 06-30-2022 10-Q
8 05-05-2022 03-31-2022 10-Q
9 03-28-2022 12-31-2021 10-K
10 11-12-2021 09-30-2021 10-Q
11 08-11-2021 06-30-2021 10-Q
12 05-11-2021 03-31-2021 10-Q
13 03-24-2021 12-31-2020 10-K
14 11-12-2020 09-30-2020 10-Q
15 08-05-2020 06-30-2020 10-Q
16 05-11-2020 03-31-2020 10-Q
17 03-30-2020 12-31-2019 10-K
18 11-07-2019 09-30-2019 10-Q
19 08-06-2019 06-30-2019 10-Q
20 05-08-2019 03-31-2019 10-Q
21 03-29-2019 12-31-2018 10-K
22 11-07-2018 09-30-2018 10-Q
23 08-07-2018 06-30-2018 10-Q
24 05-09-2018 03-31-2018 10-Q
25 04-02-2018 12-31-2017 10-K
26 11-09-2017 09-30-2017 10-Q
27 08-10-2017 06-30-2017 10-Q
28 02-14-2013 12-31-2012 10-Q
29 11-14-2012 09-30-2012 10-Q
30 08-13-2012 06-30-2012 10-Q
31 06-22-2012 03-31-2012 10-K
32 02-14-2012 12-31-2011 10-Q
33 11-14-2011 09-30-2011 10-Q
34 08-12-2011 06-30-2011 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 aileron-therapeutics-filed-us-patent-application-20240124518-methods-for-preparing-purified-polypeptide-compositions

https://ppubs.uspto.gov/dirsearch-public/print/downloadPdf/20240124518

 ladenburg-thalmann-maintains-buy-on-aileron-therapeutics-raises-price-target-to-19

Ladenburg Thalmann analyst Aydin Huseynov maintains Aileron Therapeutics (NASDAQ:ALRN) with a Buy and raises the price targe...

 aileron-therapeutics-q4-eps-154-down-from-100-yoy-cash-runway-expected-to-fund-operations-and-key-milestones-into-q4-of-2024

Aileron Therapeutics (NASDAQ:ALRN) reported quarterly losses of $(1.54) per share versus losses of $(1.00) per share from the s...

 on-feb-29-aileron-therapeutics-got-letter-from-nasdaq-that-co-has-regained-compliance-for-continued-listing-on-nasdaq

- SEC Filing

 aileron-therapeutics-and-pulmonary-care-experts-to-discuss-the-potential-implications-of-lti-03-for-idiopathic-pulmonary-fibrosis-in-virtual-key-opinion-leader-event

Aileron Therapeutics, Inc. ("Aileron") (NASDAQ:ALRN), a biopharmaceutical company advancing a novel pipeline of first-i...

 why-ups-shares-are-trading-lower-by-8-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Shares of United Parcel Service, Inc. (NYSE: UPS) fell sharply during Tuesday’s session after the company reported worse-than-e...

 why-quanex-building-products-shares-are-trading-lower-by-over-10-here-are-other-stocks-moving-in-fridays-mid-day-session

Shares of Quanex Building Products Corporation (NYSE: NX) moved lower during Friday’s session after the company reported fourth...

 why-getaround-shares-are-trading-higher-by-around-86-here-are-20-stocks-moving-premarket

Shares of Getaround, Inc. (NYSE: GETR) rose sharply in pre-market trading after the company reported a year-over-year increas...

 ladenburg-thalmann-upgrades-aileron-therapeutics-to-buy-announces-9-price-target

Ladenburg Thalmann analyst Aydin Huseynov upgrades Aileron Therapeutics (NASDAQ:ALRN) from Neutral to Buy and announces $9 p...

 aileron-therapeutics-announces-acquisition-of-lung-therapeutics-financing-proceeds-of-18m-from-a-private-placement-anticipated-to-fund-completion-of-the-ongoing-phase-1b-clinical-study-of-lti-03-in-ipf-and-for-general-corporate-purposes

Acquisition includes multiple clinical stage, orphan pulmonary disease candidates, including LTI-03, a Caveolin-1-related pepti...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION